Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) SVP William J. Regan bought 20,000 shares of the firm’s stock in a transaction dated Thursday, June 29th. The shares were purchased at an average price of $0.53 per share, with a total value of $10,600.00. Following the acquisition, the senior vice president now directly owns 172,977 shares in the company, valued at approximately $91,677.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Navidea Biopharmaceuticals Inc (NYSEMKT NAVB) traded down 5.88% during mid-day trading on Monday, hitting $0.48. The stock had a trading volume of 190,461 shares. The company has a 50-day moving average of $0.49 and a 200 day moving average of $0.54. Navidea Biopharmaceuticals Inc has a one year low of $0.26 and a one year high of $1.16. The firm has a market cap of $77.61 million and a price-to-earnings ratio of 1.00.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/03/william-j-regan-acquires-20000-shares-of-navidea-biopharmaceuticals-inc-nysemktnavb-stock.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC raised its position in shares of Navidea Biopharmaceuticals by 7.2% in the first quarter. HighTower Advisors LLC now owns 177,966 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 11,900 shares in the last quarter. Morgan Stanley raised its stake in Navidea Biopharmaceuticals by 1.0% in the first quarter. Morgan Stanley now owns 175,560 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 1,778 shares during the period. Vanguard Group Inc. raised its stake in Navidea Biopharmaceuticals by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,807,244 shares of the biopharmaceutical company’s stock worth $2,773,000 after buying an additional 253,216 shares during the period. Finally, Spark Investment Management LLC raised its stake in Navidea Biopharmaceuticals by 17.6% in the first quarter. Spark Investment Management LLC now owns 494,000 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 74,000 shares during the period.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Receive News & Ratings for Navidea Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.